Kenneth A. Foon|Dhaval Mehta|Suzanne Lentzsch|Patricia Kropf|Stanley M. Marks|Diana Lenzner|L. Pietragallo|M. Sulecki|Ahmad A. Tarhini|Michael Boyiadzis
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia
UPMC Hillman Cancer Center|UPMC Hillman Cancer Center|Temple University|UPMC Hillman Cancer Center|UPMC Hillman Cancer Center|UPMC Hillman Cancer Center|UPMC Hillman Cancer Center|UPMC Hillman Cancer Center|UPMC Hillman Cancer Center
editorchemoimmunotherapy fludarabine f cyclophosphamide c rituximab r currently considered gold standard firstline therapy chronic lymphocytic leukemia cll11 attempt reduce neutropenia maintain high response rate standarddose fcr